KARYOPHARM THERAPEUTICS INC.

(KPTI)
  Report
Delayed Nasdaq  -  05/17 04:00:00 pm EDT
5.710 USD   +4.58%
05/10Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference
PR
05/05TRANSCRIPT : Karyopharm Therapeutics Inc., Q1 2022 Earnings Call, May 05, 2022
CI
05/05KARYOPHARM THERAPEUTICS : Q1 Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Karyopharm to Present at B. Riley Securities Oncology Investor Conference

01/24/2022 | 09:12am EDT

NEWTON, Mass. - Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present virtually at the B. Riley Securities Oncology Investor Conference. The conference is being conducted in a virtual format and the presentation will take place on Friday, January 28 at 9:30 a.m. ET.

A live webcast of the presentation, along with accompanying slides, can be accessed under 'Events & Presentations' in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 30 days following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications, and has received regulatory approvals in a growing number of ex-U.S. territories and countries, including Europe (as NEXPOVIO), the United Kingdom and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in endometrial cancer, myelodysplastic syndromes and myelofibrosis.

XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

Contact:

Investors

Argot Partners

Jason Finkelstein

Matthew DeYoung

T: 212.600.1902

E: karyopharm@argotpartners.com

Media

720 Strategies

Andrew Lee

E: andrew.lee@720strategies.com

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about KARYOPHARM THERAPEUTICS INC.
05/10Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference
PR
05/05TRANSCRIPT : Karyopharm Therapeutics Inc., Q1 2022 Earnings Call, May 05, 2022
CI
05/05KARYOPHARM THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/05KARYOPHARM THERAPEUTICS INC. Management's Discussion and Analysis of Financial Conditi..
AQ
05/05Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $47.7M, vs. Street Est..
MT
05/05Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Loss $-0.53, vs. Street Est of..
MT
05/05Karyopharm Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March..
CI
05/02Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
04/28Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Cli..
AQ
04/28Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022
PR
More news
Analyst Recommendations on KARYOPHARM THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 165 M - -
Net income 2022 -173 M - -
Net Debt 2022 86,9 M - -
P/E ratio 2022 -2,55x
Yield 2022 -
Capitalization 434 M 434 M -
EV / Sales 2022 3,16x
EV / Sales 2023 2,91x
Nbr of Employees 442
Free-Float 91,1%
Chart KARYOPHARM THERAPEUTICS INC.
Duration : Period :
Karyopharm Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KARYOPHARM THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 5,46 $
Average target price 11,89 $
Spread / Average Target 118%
EPS Revisions
Managers and Directors
Richard A. Paulson President, CEO & Non-Executive Director
Michael P. Mason Chief Financial Officer, Treasurer & EVP
Reshma Rangwala Chief Medical Officer & Executive Vice President
Ronit Milstein Vice President-Operations
Lisa Meletta Chief Compliance Officer & Vice President-Legal
Sector and Competitors
1st jan.Capi. (M$)
KARYOPHARM THERAPEUTICS INC.-15.09%434
GILEAD SCIENCES, INC.-14.28%78 068
REGENERON PHARMACEUTICALS, INC.3.72%70 575
VERTEX PHARMACEUTICALS15.74%65 005
WUXI APPTEC CO., LTD.-16.20%42 275
BIONTECH SE-41.35%36 745